The Expedited Approval Scheme for Medical Device Listing Applications

1. Key takeaways

The Expedited Approval Scheme for medical device listing applications applies to Class II/III/IV general medical devices and Class B/C/D in vitro diagnostic medical devices, and 3 conditions have to be met at the same time: the product has no reports of death or serious injury either locally or globally; there is no ongoing recall, field safety corrective action or adverse event; and the product holds 2 or more valid independent marketing approvals from recognised regulatory authorities. Applicants must respond to any question raised by the Medical Device Division (MDD) within 2 weeks of notification. The scheme previously ran as a pilot, became a regular arrangement on 4 January 2022, and was extended to Class B/C/D in vitro diagnostic medical devices on 26 July 2024.

• Eligibility turns on a clean safety record rather than on technical novelty, and two of the three conditions are directed at that record.
• The scheme is open only to an existing Local Responsible Person, so a first-time applicant must complete LRP listing before it can be used at all.
• The written procedures already accepted by MDD have to cover the device being applied for, and this is checked at the point of acceptance rather than later.
• MDD retains the right to move an application back to the ordinary queue where a question is not resolved in time or a condition fails.
• Inconsistent model or product identifier wording across the dossier is treated as a substantive defect, not a clerical one.

2. Legal basis

The scheme is governed by the published notes, which set the eligibility conditions and the procedural consequences of failing them, together with the historical terms of the pilot scheme and the announcement that extended the arrangement to IVD devices. The table below lists the instruments and the provisions relied on in this article.

The notes and the two guidances are used together. The notes decide whether an application may enter the scheme at all, and the guidances decide how the dossier is assembled once it has entered. A dossier that satisfies GN-02 or GN-06 in full can still be refused entry to the scheme if the notes are not met, which is why the eligibility work belongs before dossier drafting rather than after it.

3. Expert insights

First, the threshold is a safety history rather than technical sophistication. 2 of the 3 conditions point directly at safety history: no death or serious injury, and no ongoing recall or adverse event. The logic of the scheme is to direct review resources towards products whose risk record is clean, not to reward innovation as such. A novel device with an unresolved complaint pattern is therefore a weaker candidate than a well-established device with an unblemished record, even where the novel device carries stronger published clinical data.

Second, only an existing LRP can take part. Paragraph 5 of the notes provides that only an existing Local Responsible Person is eligible. A first-time applicant has to complete LRP listing and obtain a listing number before it has any standing to use the scheme. This sequencing point is frequently discovered late, when a launch date has already been fixed, and it cannot be compressed by preparing the device dossier earlier.

Third, the scope of the procedures has to cover the product applied for. Paragraph 6 requires the applicant to confirm before submission that the device concerned is covered by the written procedures already accepted by MDD and held by the applicant. The point is often overlooked, and the consequence is that eligibility is rejected after the application has been accepted, which costs more time than a rejection at the counter would have done. Where the product sits outside the scope, the scope has to be extended first.

Fourth, the downgrade mechanism carries real weight. Paragraph 7 provides that where MDD considers a question has not been effectively resolved by the specified date, or any eligibility condition is not met, MDD reserves the right to handle the application as an ordinary application. A downgrade is not a slowing of the fast track; it is a return to the standard queue, which means the projected launch date moves by the difference between the two timelines rather than by a few weeks.

Fifth, inconsistent model wording leads directly to an unsuccessful application. Paragraph 11 makes clear that where the model or product identifier is expressed inconsistently in different parts of the dossier, the applicant must submit additional information demonstrating equivalence, and failure to provide it may result in an unsuccessful application. The requirement is mechanical but unforgiving, and it is best handled by fixing one form of wording at the start and reusing it everywhere.

4. Practical recommendations

• Run a safety history check first. Before filing, review death, serious injury, recall and adverse event records worldwide and reduce the findings to a written statement that can be placed in the dossier.
• Build an internal 2-week response mechanism. Nominate a named person who starts the internal response process within 48 hours of an MDD notification, leaving time for internal review and translation.
• Verify the scope of procedures. Confirm that the product falls within the written procedures already accepted by MDD, and apply to extend the scope first where it does not.
• Standardise model wording. Place a model and product identifier concordance table on the first page of the dossier and use the same wording throughout the document.
• Prepare an exit plan. If the application is downgraded to an ordinary application, reschedule on the standard 12-week cycle rather than assuming a short delay.

5. Verification checklist

• □ Independent marketing approvals from 2 or more recognised jurisdictions are held
• □ A written confirmation states that there are no reports of death or serious injury locally or globally
• □ A written confirmation states that there is no ongoing recall, field safety corrective action or adverse event
• □ The applicant already holds an LRP listing number
• □ The product applied for falls within the written procedures accepted by MDD
• □ An internal mechanism exists for responding to MDD questions within 2 weeks
• □ Model and product identifier wording is consistent throughout the dossier

Regulatory information verified to 29 October 2026. The legislation, guidance and effective dates described in this article are limited to what the official sources listed under Legal basis had published on that date; where an official document has since been updated, the most recent published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages MDACS listing applications across all risk classes, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com